Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 1/20 | 0.38 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7788542 | 0.93 | PLG (0.37) | PSEN1PLGF10PLAUKLKB1 | |
| SCHEMBL7797943 | 0.93 | PSEN1 (0.35) | PSEN1PLGF10PLAUKLKB1 | |
| SCHEMBL7799060 | 0.87 | PLG (0.41) | PSEN1PLGF10PLAUKLKB1 | |
| SCHEMBL7795663 | 0.83 | PLG (0.39) | PSEN1PLGF10PLAUKLKB1 | |
| SCHEMBL7795225 | 0.79 | PLG (0.37) | PLGF10PLAUKLKB1ALOX5 | |
| SCHEMBL7795257 | 0.77 | PPARG (0.34) | PLGF10PLAUKLKB1ALOX5 | |
| SCHEMBL7795590 | 0.74 | PPARG (0.34) | PLGF10PLAUKLKB1ALOX5 | |
| SCHEMBL7788510 | 0.72 | PSEN1 (0.39) | PSEN1ALOX5PTPN1GSTO1NR1I2 | |
| SCHEMBL7795661 | 0.72 | PPARG (0.31) | PLGF10PLAUKLKB1ALOX5 | |
| SCHEMBL7799047 | 0.71 | PSEN1 (0.45) | PSEN1ALOX5PTPN1GSTO1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2001-08-09 | — | — | US | disclosed |
| US-6225480-B1 | FOR SYNTHESIS OF ORGANIC COMPOUNDS CONTAINING--NH--GROUPS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-01 | — | — | US | disclosed |
| EP-0948480-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| WO-1998029386-A1 | SULPHONYL COMPOUNDS FOR USE AS LINKERS IN SOLID PHASE AND COMBINATORIAL SYNTHESIS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010012901-A1 | Sulphonyl compounds for use as linkers in solid phase and combinatorial synthesis | H1-0, H1-2, ASH2L | PSEN1 3461/4885PLG 2853/4885F10 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.